ICLR

NASDAQ Healthcare

ICON plc - Ordinary Shares

Diagnostics & Research

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

๐Ÿ“Š Market Data
Price$112.85
Volume961,043
Market Cap8.78B
Beta1.280
RSI (14-Day)52.4
200-Day MA$156.23
50-Day MA$106.98
52-Week High$211.00
52-Week Low$66.57
P/E Ratio15.21
Forward P/E9.54
Price / Book0.92
๐ŸŽฏ Investment Strategy Scores

ICLR scores across each investment strategy. Higher is better for that strategy's goals.

High dividend yield + low volatility
๐Ÿš€ Moon Shot 74/100โ–ฒ +8
High growth potential (high beta + oversold)
๐Ÿ”ช Falling Knife 91/100โ–ฒ +7
Contrarian plays (oversold + below moving average)
๐ŸŽˆ Over-Hyped 41/100โ–ผ -18
Overbought stocks (potential short candidates)
Large-cap, institutional-quality stocks
๐Ÿ” Strategy Interpretation

Best fit: ๐Ÿ”ช Falling Knife (91/100) โ€” this strategy Contrarian plays (oversold + below moving average).

Lowest fit among scored strategies: ๐Ÿ’ฐ Dividend Daddy (18/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find ICLR in your text

Paste any article, transcript, or post โ€” the tool will extract ICLR and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.